BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio Pharma (BBIO) announced a nationwide education effort with community partners to increase awareness of transthyretin amyloid cardiomyopathy, or ATTR-CM. The condition involves protein buildup in the heart and can be overlooked because symptoms resemble other heart conditions or aging.
The effort begins with an October 6 YouTube premiere at 6:00 pm EDT, moderated by Sway Calloway and featuring ATTR-CM advocate Howard “H” White, physician Albert J. Hicks III and Hip Hop Public Health founders. Community partners will host or support viewings and educational programming at 40 locations nationwide. Community conversations and programming will continue leading up to World Amyloidosis Day on October 26.
BridgeBio Pharma (BBIO) presented exploratory cardiac results from the 12-month interim analysis of its Phase 3 FORTIFY trial of BBP-418. Among evaluable participants with elevated baseline high-sensitivity troponin I, a blood marker of heart injury, 100% receiving BBP-418 normalized by Month 12 versus 40% on placebo (p=0.0248). The marker declined more with treatment, with an adjusted mean difference of -17.8 ng/L (p=0.0443). Stable or improved left ventricular ejection fraction, a measure of heart pumping function, occurred in 54% versus 25% (p=0.0262).
Mean glycosylated alpha-dystroglycan, a muscle-stabilizing protein, reached asymptomatic carrier levels by Month 3 and remained there through Month 12. All primary and secondary endpoints were met at the interim analysis. BridgeBio views the findings as supporting disease-modifying potential. BBP-418 is under FDA Priority Review, with a target action date of November 27, 2026.
BridgeBio Pharma (BBIO) reported peer-reviewed real-world data showing acoramidis reduced early clinical worsening versus tafamidis in adults with ATTR-CM.
In a retrospective U.S. claims study of newly treated patients, acoramidis was associated with a 34% lower risk of a composite endpoint (diuretic intensification, heart failure hospitalization, all-cause mortality; HR 0.66; p=0.046) compared with tafamidis over a mean 4.6‑month follow-up. Acoramidis was also linked to a 43% reduction in risk of diuretic intensification (HR 0.57; p=0.021) and a 48% reduction in initiation or dose-equivalent escalation of oral loop diuretics (HR 0.52; p=0.014). Separation in outcomes appeared within weeks of treatment initiation and widened over time. Background heart failure therapies were well balanced between groups, and multiple falsification analyses were nonsignificant. The company highlighted real-world evidence limitations and noted longer-term data and an additional independent EHR-based study are forthcoming.
BridgeBio Pharma (BBIO) granted equity awards under Nasdaq Listing Rule 5635(c)(4) to 36 new employees, effective September 18, 2026.
The compensation committee approved restricted stock unit grants covering an aggregate of 63,009 common shares. For each employee, one-fourth of the RSU award will vest on November 16, 2027, and the remaining three-fourths will vest in equal quarterly installments over three years thereafter, subject to continued employment with BridgeBio or its subsidiaries on each vesting date. The inducement awards were granted under the company’s equity plan, originally adopted in November 2019 and amended and restated on February 10, 2023 and December 13, 2023.
BridgeBio Pharma (BBIO) reported new exploratory Phase 3 PROPEL 3 data showing that 52 weeks of oral infigratinib in children with achondroplasia led to favorable trends versus placebo in sleep apnea, ear infections, and body composition.
Mean total Apnea-Hypopnea Index increased 10.4% with infigratinib versus 49.2% with placebo, and was unchanged versus a 63.2% increase in placebo among children under 8. The annualized otitis media rate was 38% lower with infigratinib versus placebo, and 47% lower in children under 8. Body composition analyses showed smaller BMI increases and lower gains in fat and visceral fat, with greater lean mass gain versus placebo.
Across up to three years of PROPEL treatment, height Z-score improved by +0.92 SD and upper-to-lower body ratio by -0.15, with no new safety signals. BridgeBio has submitted an NDA to the FDA, anticipates a potential U.S. launch in mid-2027, and plans an EMA MAA in Q4 2026.
BridgeBio Pharma (BBIO) will present new data on oral infigratinib in achondroplasia at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026 in Marseille, France, on September 8–10, 2026.
The company highlights a late-breaking oral presentation from the randomized PROPEL 3 trial evaluating oral infigratinib’s impact on medical complications in children with achondroplasia, to be delivered by Julie Hoover-Fong, M.D., Ph.D., on September 9 at 10:00 am CEST. Two posters will cover longer-term efficacy and safety data and the PROPEL Infant & Toddler Phase 2/2b study in children under 3 years old, alongside an ePoster on medical challenges and functional impacts of hypochondroplasia. Oral infigratinib is described as an investigational FGFR3 inhibitor intended to improve bone growth in skeletal dysplasias such as achondroplasia and hypochondroplasia.
BridgeBio (Nasdaq: BBIO) announced that its management team will participate in several healthcare investor conferences in September 2026, including events hosted by Wells Fargo, Cantor, Morgan Stanley, and Bernstein in Boston and New York on dates between September 9 and September 23.
Live webcasts of the fireside chats will be available via the Investors “Events and Presentations” page on BridgeBio’s website, with replays accessible for 90 days. BridgeBio describes itself as a commercial-stage biopharmaceutical company developing medicines for genetic conditions using a decentralized hub-and-spoke model.
BridgeBio (Nasdaq: BBIO) announced a voluntary agreement with the U.S. government aimed at expanding access to its medicines, especially for Medicaid patients, while lowering costs for American patients. Under the deal, BridgeBio will expand state Medicaid access to its currently marketed medicine via the GENEROUS Model.
According to BridgeBio, Attruby will continue to be offered via Medicare Part D without future pricing mandates, and the ForgingBridges copay assistance program remains unchanged, potentially reducing out-of-pocket costs to as little as $0 per month for qualifying patients. The company also highlighted three additional medicines under FDA review for rare genetic conditions.
BridgeBio Pharma (Nasdaq: BBIO) reported new Phase 3 ATTRibute‑CM analyses for Attruby (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR‑CM), showing CMR‑based evidence that long‑term treatment can potentially reverse cardiac structural disease progression and functional decline through 42 months in a substantial subset of patients.
In the CMR completer analysis, clinically meaningful improvement in left ventricular systolic function was seen in 54% of acoramidis‑treated patients versus 20% on placebo at Month 30, with 53% improvement at Month 42 in continuous‑treatment patients. A conservative analysis showed improvement in roughly one‑third of treated patients and favorable LV mass remodeling.
A post‑hoc analysis found acoramidis reduced days lost to death or cardiovascular hospitalization and preserved an additional 38 days alive and out of hospital over 30 months, increasing to 65 observed and up to 94 modeled days over three years. In the open‑label extension through Month 54, continuous acoramidis in variant ATTR‑CM, including p.Val142Ile carriers, was associated with markedly lower all‑cause and cardiovascular mortality versus placebo‑to‑acoramidis, durable biomarker effects, improved quality of life and heart‑failure status, and a generally well‑tolerated safety profile.
BridgeBio (Nasdaq: BBIO) reported dosing the first participant in ASCEND-ATTR, a Phase 3b/4, single-arm, open-label study evaluating long-term treatment with acoramidis (Attruby) in adults with transthyretin amyloid cardiomyopathy (ATTR-CM). The trial aims to further characterize improvement in cardiac structure, function, and amyloid burden.
According to BridgeBio, ASCEND-ATTR will enroll about 150 participants, using annual cardiovascular magnetic resonance (CMR) and echocardiography over 36 months. The primary endpoint is Month 36 CMR responder status based on improved left ventricular systolic function, with secondary endpoints including additional imaging, biomarkers, and amyloid burden. Prior ATTRibute-CM CMR substudy data suggested improvements in LVMi, LVSVi, LVEF and amyloid regression in a subset of patients, supporting this long-term evaluation of acoramidis, a selective, orally administered near-complete (≥90%) TTR stabilizer. Attruby is already indicated to treat ATTR-CM in adults to reduce cardiovascular death and related hospitalizations.